So Acadia just got rejected by EU regulators for their Rett syndrome drug trofinetide. CHMP said the treatment effect was too modest and didn't capture all the core symptoms they wanted to see. Pretty rough timing honestly. But here's the thing - the FDA already approved it in the US back in 2023 under the brand Daybue, and it's actually selling pretty well. Last year Daybue hit $391M in sales, up 12% YoY. Their other drug Nuplazid for Parkinson's psychosis did even better at $680M. The company's projecting around $1.7B combined revenue by 2028 from these two products. What's interesting is they just got approval for a new powder formulation called Daybue Stix in late 2025 and are rolling it out starting next quarter. So while the EU setback sucks, the Rett syndrome market opportunity in the US seems solid and they're expanding the product line. They're planning to request a re-examination in Europe anyway. Stock is down 7.9% over the past six months while the biotech sector rallied 18%, so there's been some pressure. But if those sales keep growing and the new formulation gains traction, could be a decent recovery story. Curious if anyone else is watching this one or thinks the EU rejection signals something bigger about the drug's actual efficacy.